Society Letters

Endocrine Society Comments on FDA Global Rare Disease Network

July 28, 2020

To: Lowell Schiller, Principal Associate Commissioner for Policy, U.S. Food and Drug Administration

"Several endocrine conditions, including acromegaly, adrenocortical carcinoma, growth hormone deficiency, Cushing’s syndrome, and familial chylomicronemia syndrome (FCS), qualify as rare diseases, and patients still lack effective treatments for many of these and other conditions. We enthusiastically support the Rare Diseases Cures Accelerator and welcome the opportunity to participate in a global clinical trial network for rare diseases. Our comments are aimed at ensuring the immediate and long-term success of such an initiative."

arrowRead the Full Summary

Last Updated:
Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.